Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 14,286 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 14,286 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $70.00, for a total transaction of $1,000,020.00. Following the completion of the sale, the chief executive officer directly owned 47,420 shares in the company, valued at $3,319,400. This represents a 23.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, August 18th, Ryan Fukushima sold 41,095 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total transaction of $2,038,722.95.
• On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $50.04, for a total transaction of $1,000,800.00.
• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The shares were sold at an average price of $46.19, for a total transaction of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The stock was sold at an average price of $57.39, for a total transaction of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total value of $600,000.00.

Tempus AI Price Performance

Shares of Tempus AI stock traded up $2.56 during trading on Tuesday, hitting $68.73. 8,855,085 shares of the stock traded hands, compared to its average volume of 6,061,404. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The stock has a market cap of $12.40 billion, a price-to-earnings ratio of -47.73 and a beta of 3.58. The firm’s fifty day moving average is $53.21 and its 200-day moving average is $51.38. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same period last year, the firm posted ($0.22) earnings per share. The business’s revenue was up 21.6% compared to the same quarter last year. Research analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pictet Asset Management Holding SA raised its position in shares of Tempus AI by 291.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after purchasing an additional 36,096 shares during the period. Bogart Wealth LLC boosted its holdings in shares of Tempus AI by 365,087.5% during the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock worth $3,450,000 after buying an additional 58,414 shares during the period. Eagle Health Investments LP acquired a new position in Tempus AI in the 1st quarter valued at about $11,588,000. Alethea Capital Management LLC bought a new position in Tempus AI in the 4th quarter valued at about $1,863,000. Finally, Hussman Strategic Advisors Inc. lifted its position in Tempus AI by 100.0% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the company’s stock worth $2,480,000 after acquiring an additional 21,000 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Stifel Nicolaus dropped their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a research note on Monday, August 3rd. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of Tempus AI in a report on Friday, July 31st. Piper Sandler reduced their price objective on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a research report on Tuesday, August 4th. Finally, BTIG Research lifted their price objective on Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Tempus AI has an average rating of “Hold” and an average price target of $65.69.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.